153 related articles for article (PubMed ID: 20708696)
1. Girls' preferences for HPV vaccination: a discrete choice experiment.
de Bekker-Grob EW; Hofman R; Donkers B; van Ballegooijen M; Helmerhorst TJ; Raat H; Korfage IJ
Vaccine; 2010 Sep; 28(41):6692-7. PubMed ID: 20708696
[TBL] [Abstract][Full Text] [Related]
2. Adolescent girls' preferences for HPV vaccines: a discrete choice experiment.
Brown DS; Poulos C; Johnson FR; Chamiec-Case L; Messonnier ML
Adv Health Econ Health Serv Res; 2014; 24():93-121. PubMed ID: 25244906
[TBL] [Abstract][Full Text] [Related]
3. Have preferences of girls changed almost 3 years after the much debated start of the HPV vaccination program in The Netherlands? A discrete choice experiment.
Hofman R; de Bekker-Grob EW; Richardus JH; de Koning HJ; van Ballegooijen M; Korfage IJ
PLoS One; 2014; 9(8):e104772. PubMed ID: 25136919
[TBL] [Abstract][Full Text] [Related]
4. Parents' preferences for vaccinating daughters against human papillomavirus in the Netherlands: a discrete choice experiment.
Hofman R; de Bekker-Grob EW; Raat H; Helmerhorst TJ; van Ballegooijen M; Korfage IJ
BMC Public Health; 2014 May; 14():454. PubMed ID: 24885861
[TBL] [Abstract][Full Text] [Related]
5. Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus.
Brown DS; Johnson FR; Poulos C; Messonnier ML
Vaccine; 2010 Feb; 28(7):1702-8. PubMed ID: 20044060
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
7. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
8. [Advisory report from the Health Council of the Netherlands to include human papillomavirus vaccination in the national immunisation programme for the prevention of cervical cancer].
Boeke AJ
Ned Tijdschr Geneeskd; 2008 Apr; 152(17):981-3. PubMed ID: 18549170
[TBL] [Abstract][Full Text] [Related]
9. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
10. [Vaccines against human papillomavirus (HPV); between registration and implementation].
van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
[TBL] [Abstract][Full Text] [Related]
11. Survey of girls' recall of a film providing information on human papillomavirus and cervical cancer 6 months after an offer of vaccination.
Brabin L; Stretch R; Roberts SA; Elton P; Baxter D; McCann R
Vaccine; 2010 Jun; 28(25):4210-4. PubMed ID: 20399829
[TBL] [Abstract][Full Text] [Related]
12. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
13. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
14. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
16. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
17. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
[TBL] [Abstract][Full Text] [Related]
18. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
19. [Safety of the bivalent human papillomavirus vaccine--results following administration of more than 192,000 doses].
van der Maas NA; Kemmeren JM; de Melker HE
Ned Tijdschr Geneeskd; 2009; 153():A964. PubMed ID: 19930738
[TBL] [Abstract][Full Text] [Related]
20. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
